Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients

European Journal of Cancer(2024)10.1016/j.ejca.2024.115119Source: DataRank Database

Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients is a research paper published in European Journal of Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: hybridTopics (46)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (21)

G.V. Long,John O. Larkin ORCID,Jedd D. Wolchok ORCID,J.C. Hassel,D. Schadendorf

Live enrichment

PubMed:39612757

NCI NIH HHS

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

hybridLicense: cc-by

publisherhttps://doi.org/10.1016/j.ejca.2024.115119

publisherhttps://api.elsevier.com/content/article/PII:S095980492401726X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S095980492401726X?httpAccept=text/plain

repositoryhttps://lirias.kuleuven.be/retrieve/80b511b1-fad6-4634-86f2-a001f17f2000

https://pubmed.ncbi.nlm.nih.gov/39612757

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansMelanomaSkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTreatment OutcomeTime FactorsAdultAgedAged, 80 and overMiddle AgedFemaleMaleIpilimumabNivolumabProgression-Free Survival

Keywords

Prognostic factorsIpilimumabLong-term SurvivalClinical ResponseNivolumabAdvanced MelanomaMaleAdultTime FactorsSkin NeoplasmsMedizin610MELANOMA1117 Public Health and Health Services3211 Oncology and carcinogenesisAntineoplastic Combined Chemotherapy ProtocolsHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisAgedAged, 80 and overScience & TechnologyMiddle AgedProgression-Free SurvivalTreatment OutcomeOncologySURVIVALFemaleLife Sciences & Biomedicine